References
1. Zhu N, Zhang D, Wang W et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020, 382:727-733.
2. Wu F, Zhao S, Yu B et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579:265-269.
3. Casellas F, Arenas JI, Baudet JS et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005, 11:488-496.
4. Barreiro-de Acosta M, Marin-Jimenez I, Panadero A et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. Gastroenterol Hepatol 2018, 41:118-127.
5. Garcia Calvo E, Dura Gil M, Velayos Jimenez B et al. Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients. Rev Esp Enferm Dig 2021, 113:512-518.
6. Rubin DT, Feuerstein JD, Wang AY et al. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology 2020.
7. Ozamiz-Etxebarria N, Dosil-Santamaria M, Picaza-Gorrochategui M et al. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. Cad Saude Publica 2020, 36:e00054020.
8. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
9. Walmsley RS, Ayres RC, Pounder RE et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
10. Jowett SL, Seal CJ, Phillips E et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003, 38:164-171.
11. Lopez-Vivancos J, Casellas F, Badia X et al. Validation of the spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease. Digestion 1999, 60:274-280.
12. Casellas F, Alcala MJ, Prieto L et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004, 99:457-461.
13. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983, 24:385-396.
14. Remor E. Psychometric properties of a European Spanish version of the Perceived Stress Scale (PSS). Span J Psychol 2006, 9:86-93.
15. Huaman JW, Casellas F, Borruel N et al. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. J Crohns Colitis 2010, 4:637-641.
16. Herrera-deGuise C, Casellas F, Robles V et al. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents. J Gastroenterol Hepatol 2015, 30:286-291.
17. Marques-Cami M, Robles Alonso V, Borruel N et al. Normalization of long-term quality of life in Crohn's disease patients receiving ustekinumab. Rev Esp Enferm Dig 2021, 113:313-317.
18. Casellas F, Rodrigo L, Nino P et al. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007, 13:1395-1400.
19. El Hajra I, Calvo M, Santos Perez E et al. Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit. Rev Esp Enferm Dig 2021, 113:98-102.